September 2025
1. COOK JD, Hooey PB, Salazar KC, Clark JR, et al
   Results of TOR001: an open-label single patient study using targeted bacteriophage therapy for the treatment of a chronic urinary tract infection.
   Int J Antimicrob Agents. 2025 Sep 8:107613.
   

   >> Share

   
   
2. BENITEZ-CANO A, Liu X, Xu H, Tang X, et al
   Optimizing Linezolid Dosing for Nosocomial Urinary Tract Infections in Critically Ill Patients with Renal Impairment.
   Int J Antimicrob Agents. 2025 Sep 5:107610.
   

   >> Share

   
   
3. ABRIL D, Solorzano P, Leal AL, Forero-Hurtado D, et al
   Ceftazidime/avibactam resistance in Enterobacter cloacae due to the acquisition of a small pHAD28-like plasmid harbouring bla(KPC-33).
   Int J Antimicrob Agents. 2025;66:107540.
   

   >> Share

   
   September 2024
4. LI P, Xu Q, Ding L, Zhang X, et al
   Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
   Int J Antimicrob Agents. 2024;64:107277.
   

   >> Share

   
   
5. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
   Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
   Int J Antimicrob Agents. 2024;64:107259.
   

   >> Share

   
   August 2024
6. YANG W, Chen J, Yang F, Ji P, et al
   Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
   Int J Antimicrob Agents. 2024;64:107211.
   

   >> Share

   
   
7. GIMENEZ-PEREZ M, Hernandez S, Padulles A, Boix-Palop L, et al
   Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia.
   Int J Antimicrob Agents. 2024;64:107202.
   

   >> Share

   
   July 2024
8. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
   Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
   Int J Antimicrob Agents. 2024;64:107186.
   

   >> Share

   
   December 2023
9. SHI H, Zeng L
   Comment on: Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
   Int J Antimicrob Agents. 2023 Dec 9:107059.
   

   >> Share

   
   November 2023
10. KIM C, Choi YH, Choi JY, Choi HJ, et al
    Translation of Machine Learning-Based Prediction Algorithms to Personalised Empiric Antibiotic Selection: A Population-Based Cohort Study.
    Int J Antimicrob Agents. 2023;62:106966.
    

    >> Share

    
    September 2023
11. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    

    >> Share

    
    
12. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    

    >> Share

    
    April 2023
13. HUNG KC, Tsai WW, Hsu CW, Lai CC, et al
    Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials.
    Int J Antimicrob Agents. 2023 Apr 24:106830.
    

    >> Share

    
    
14. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    

    >> Share

    
    March 2023
15. DE OCA JEM, Veve MP, Zervos MJ, Kenney RM, et al
    Aminopenicillins versus Non-aminopenicillins for Treatment of Enterococcal Lower Urinary Tract Infections.
    Int J Antimicrob Agents. 2023 Mar 31:106800.
    

    >> Share

    
    August 2022
16. BELMONT-MONROY L, Ribas-Aparicio RM, Gonzalez-Villalobos E, Perez-Ramos JA, et al
    Molecular typification of Escherichia coli from community-acquired urinary tract infections in Mexico.
    Int J Antimicrob Agents. 2022 Aug 26:106667.
    

    >> Share

    
    April 2022
17. FOSSE PE, Brinkman KM, Brink HM, Conner CE, et al
    Comparing outcomes among outpatients treated for pyelonephritis with oral cephalosporins versus first-line agents.
    Int J Antimicrob Agents. 2022;59:106560.
    

    >> Share

    
    March 2022
18. TUTONE M, Johansen TEB, Cai T, Mushtaq S, et al
    SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Int J Antimicrob Agents. 2022 Mar 17:106574.
    

    >> Share

    
    January 2022
19. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share